跳至主要内容
临床试验/ISRCTN86496888
ISRCTN86496888已完成未知

Assessment of epithelial permeability in asthma through nuclear imaging: an observational trial

Southampton University Hospitals NHS Trust (UK)0 个研究点目标入组 40 人开始时间: 2009年7月28日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. Subject must understand the procedures of the study and agree to participation in the study by providing written informed consent
  • 2. Subject considered fit enough to undergo lung function testing including provocation tests
  • 3. Either gender
  • 4. Age 18 - 55 years at screening
  • Group specific:
  • 1. Healthy controls:
  • 1.1. Lifelong non-smoker
  • 1.2. No history suggestive of airways disease
  • 1.3. Normal spirometry, normal exhaled nitric oxide (NO), provocative concentration causing a 20% fall in forced expiratory volume in one second (FEV1) (PC20) (metacholine) greater than 8 mg/ml (non-cumulative)
  • 1.4. No signs of concurrent respiratory infection at time of scanning or within previous 8 weeks
  • 1.5. No significant cardiopulmonary/hepatic or renal co-morbidity
  • 2. Smokers:
  • 2.1. Daily smokers of tobacco cigarettes
  • 2.2. Normal spirometry, normal exhaled NO, PC20 (metacholine) greater than 8 mg/ml (non-cumulative)
  • 2.3. No signs of concurrent respiratory infection at time of scanning or within previous 8 weeks
  • 3. Asthmatics - controlled:
  • 3.1. Asthma defined as per BTS guidelines, on treatment with inhaled corticosteroids +/- long-acting beta-agonists
  • 3.2. Lifelong non-smokers (never smoked)
  • 3.3. Clinically stable with FEV1 greater than 70% post-bronchodilator use, with use of rescue bronchodilators less than 3 x week
  • 3.4. No signs of concurrent respiratory infection at time of scanning or within previous 8 weeks
  • 4. Asthmatics - uncontrolled:
  • 4.1. Asthma defined as per BTS guidelines, on treatment with inhaled corticosteroids +/- long-acting beta-agonists
  • 4.2. Lifelong non-smokers (never smoked)
  • 4.3. Use of rescue bronchodilator greater than 3 times a week
  • 4.4. No signs of concurrent respiratory infection at time of scanning or within previous 8 weeks

排除标准

  • 1. Pregnancy (where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotrophin [hCG] laboratory test greater than 5 mIU/ml), an intention to become pregnant or breast-feeding (lactating)
  • 2. Subjects with active lung disease other than asthma
  • 3. Significant medical co-morbidity which in the view of the investigator could impact on the interpretation of results or participation in the trial
  • 4. Active cancer or a history of cancer or radiotherapy
  • 5. Current/previous users of recreational inhaled illicit drugs, e.g. cannabis, crack cocaine, etc.
  • 6. Inability to lie flat for scan for 2 hours
  • 7. Those who have participated in a clinical trial involving an investigational or marketed drug within 12 weeks of screening, or participated in any study involving radiation within 12 months of screening
  • 8. Those in any situation which, in the opinion of the investigator, may interfere with optimal participation in the study
  • 9. Those unable to optimally perform the breathing manoeuvres required for lung function testing, or deposition of the radio-labelled aerosol
  • 10. Signs of concurrent respiratory tract infection on examination at the time of scanning or within previous 8 weeks (can be rescreened after 8 weeks if otherwise eligible)

研究者

发起方
Southampton University Hospitals NHS Trust (UK)

相似试验

Assessment of epithelial permeability in asthma... | 临床试验